Informex news - round-up
International Specialty Chemicals, and its subsidiary Chemfinet Services have entered into an agreement with Indian partners to construct a cGMP kilo lab facility in Chennai. The facility will allow Chemfinet to control its own production
International Specialty Chemicals, and its subsidiary Chemfinet Services have entered into an agreement with Indian partners to construct a cGMP kilo lab facility in Chennai. The facility will allow Chemfinet to control its own production
Altus Biotransformation, a division of Altus Biologics, has appointed Frances H Arnold to its scientific advisory board. She will aid the direction of Altus' development of highly active and robust biocatalysts for the pharma industry.
Diversa Corp has licenced a proprietary enzyme for the biocatalytic synthesis of a pharmaceutical intermediate to BASF, who will produce the biocatalyst and apply it to one of its processes to synthesise a chiral intermediate.
Cambridge Major, the US outsourcing company, says that its 50,000ft2 facility near Milwaukee is on schedule for completion in July 2004. IT will house over 20 reactors from 25 gallons to 500 gallons, have a large scale cryogenics facility, r&d labs, GMP compliant kilo lab suites and analytical, spectroscopy, and high potency suites.
'Having the full process under one roof will enable us to better address the needs of the pharma and biotech industries,' commented Cambridge Major president and ceo, Michael Major.
InnoCentive has expanded its relationship with leading scientific universities across China and Russia. It announced partnerships with Kazan University, Russia; Beijing University of Chemical Technology; Fudan University; Lanzhou University, and Peking University, China. 'Russia and China are both known for their rich history of scientific innovation, and InnoCentive's partnetships will bring together world-class scientists irrespective of where they are in the world,' commented InnoCentive president Darren Carroll.
Ultrafine, the Manchester, UK-based development company, has upgraded its kilo lab capabilities to include new 50l and 20l vessels, a 20l Hastelloy pressure vessel, environmental control systems, and a 10l wiped film evaporator. Mike Harris, head of business development said: 'This expansion underpins our growth as a chemical development company.'
Irix Pharmaceuticals, from Florence, SC, US, has upgraded its facilities to allow Phase II, cGMP work production to take place. Its other site in Greenville, SC is Phase III compliant, and can offer registration batches, validation and onto launch and commercialisation.
JFC Technologies from Bound Brook, NJ, US, broke ground on its state-of-the-art, multipurpose pharmaceutical facility in Ningbo, China. The construction is set to begin immediately and the firm expects to have the facility fully operational by the second quarter of 2005. The first phase will consist of three buildings totalling 50,000ft2.
